Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The importance of early treatment in MGRS & the role of the MDT

Artur Jurczyszyn • 26 Aug 2022
IMS 2022
Multiple Myeloma

Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, comments on the importance of early treatment of patients with monoclonal gammopathy of renal significance (MGRS) with autologous transplantation, highlighting the role of the multidisciplinary team (MDT) in the management of these patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Artur Jurczyszyn

2:20
Aims & projects of the Myeloma Treatment Foundation Centre in Poland
Artur Jurczyszyn • 26 Aug 2022
1:21
The impact of physical activity in patients with multiple myeloma
Artur Jurczyszyn • 26 Aug 2022
1:13
The importance of bone disease control in multiple myeloma
Artur Jurczyszyn • 26 Aug 2022
1:10
Latest developments in the treatment of EMD in myeloma
Artur Jurczyszyn • 30 Apr 2021

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals